NCT07063225 2025-07-14
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04600960 2025-02-24
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05218226 2025-02-24
Avatrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05236582 2025-02-24
Herombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06201663 2024-01-11
Romiplostim in Chemotherapy-Induced Thrombocytopenia
Ain Shams University
Phase 3 Unknown
NCT06099925 2023-10-25
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05688306 2023-01-18
To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment
Liaoning Cancer Hospital & Institute
Completed
NCT03049774 2017-02-10
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
Angde Biotech Pharmaceutical Co., Ltd.
Unknown